David Olmos Selected Research

apalutamide

12/2023	Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
1/2023	Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
3/2022	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
2/2022	Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
9/2021	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer.
7/2021	Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
1/2021	Apalutamide and Overall Survival in Prostate Cancer.
1/2021	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
1/2020	Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
9/2019	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Olmos Research Topics

Disease

64	Prostatic Neoplasms (Prostate Cancer) 03/2024 - 04/2009
39	Neoplasms (Cancer) 07/2023 - 12/2005
16	Neoplasm Metastasis (Metastasis) 03/2024 - 04/2009
7	Fatigue 01/2020 - 03/2010
6	Exanthema (Rash) 01/2023 - 11/2014
6	Circulating Neoplastic Cells 05/2021 - 04/2009
5	Disease Progression 11/2023 - 08/2009
5	Nausea 01/2020 - 03/2010
5	Sarcoma (Soft Tissue Sarcoma) 01/2013 - 02/2010
4	Vomiting 10/2013 - 02/2010
3	Carcinogenesis 09/2016 - 09/2011
3	Hodgkin Disease (Hodgkin's Disease) 05/2015 - 03/2006
3	Hyperglycemia 11/2014 - 03/2010
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2011 - 02/2010
2	Pain (Aches) 07/2023 - 01/2020
2	Anemia 01/2023 - 01/2020
2	Rhabdomyosarcoma 01/2017 - 01/2011
2	Colorectal Neoplasms (Colorectal Cancer) 12/2011 - 01/2009
1	Disease Resistance 03/2024
1	Bone Resorption 10/2023
1	Breast Neoplasms (Breast Cancer) 07/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Sepsis (Septicemia) 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 10/2021
1	Myocardial Infarction 10/2021
1	Pneumonia (Pneumonitis) 10/2021
1	Microsatellite Instability 01/2021
1	Arthralgia (Joint Pain) 01/2020
1	Weight Loss (Weight Reduction) 01/2020
1	Frailty 01/2020
1	Hypothyroidism 04/2018

Drug/Important Bio-Agent (IBA)

18	Biomarkers (Surrogate Marker)IBA 03/2024 - 12/2011
12	abirateroneIBA 11/2023 - 10/2018
11	apalutamideIBA 12/2023 - 04/2018
11	enzalutamideIBA 11/2023 - 01/2019
9	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 09/2016
8	AndrogensIBA 07/2023 - 04/2009
8	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 04/2018
8	Docetaxel (Taxotere)FDA Link 12/2021 - 03/2010
7	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 12/2011
7	Abiraterone AcetateIBA 01/2023 - 04/2009
7	Hormones (Hormone)IBA 11/2022 - 04/2009
6	olaparibIBA 11/2023 - 01/2020
6	Insulin-Like PeptidesIBA 09/2011 - 02/2010
5	taxaneIBA 07/2023 - 01/2019
5	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 09/2016
5	Prostate-Specific Antigen (Semenogelase)IBA 02/2022 - 04/2009
4	niraparibIBA 07/2023 - 09/2021
4	Monoclonal AntibodiesIBA 04/2013 - 03/2010
3	Radium-223IBA 10/2023 - 09/2017
3	ipatasertibIBA 01/2023 - 09/2021
3	Prednisone (Sone)FDA LinkGeneric 01/2023 - 10/2018
3	PlatinumIBA 01/2021 - 01/2017
3	MK 2206IBA 02/2015 - 12/2011
3	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 03/2010 - 06/2009
2	Alkaline PhosphataseIBA 10/2023 - 03/2012
2	Poly Adenosine Diphosphate RiboseIBA 07/2023 - 01/2020
2	Prednisolone (Predate)FDA LinkGeneric 01/2023 - 10/2021
2	Circulating Tumor DNAIBA 01/2023 - 01/2023
2	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2012
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
2	cabazitaxel FDA Link 09/2021 - 01/2019
2	Taxoids (Taxanes)IBA 05/2021 - 01/2021
2	Dexamethasone (Maxidex)FDA LinkGeneric 10/2018 - 08/2009
2	PolyaminesIBA 01/2018 - 01/2017
2	Cell-Free Nucleic AcidsIBA 01/2018 - 12/2011
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2017 - 04/2016
2	EnzymesIBA 05/2015 - 10/2013
2	LigandsIBA 04/2013 - 03/2010
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 03/2012 - 06/2009
2	AlbuminsIBA 03/2012 - 06/2009
2	Insulin (Novolin)FDA Link 12/2011 - 05/2010
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 03/2010 - 02/2010
2	figitumumabIBA 03/2010 - 02/2010
1	RadiumIBA 10/2023
1	Collagen Type I (Type I Collagen)IBA 10/2023
1	pyridinolineIBA 10/2023
1	Adenosine (Adenocard)FDA LinkGeneric 07/2023
1	antiarrhythmic peptide (AAP)IBA 01/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	darolutamideIBA 03/2022
1	Androgen Antagonists (Antiandrogens)IBA 03/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	rucaparibIBA 09/2021
1	talazoparibIBA 09/2021
1	Phenobarbital (Luminal)FDA Link 07/2021
1	pembrolizumabIBA 01/2021
1	Cisplatin (Platino)FDA LinkGeneric 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	SteroidsIBA 10/2018
1	MicroRNAs (MicroRNA)IBA 01/2017
1	S-adenosyl-3-methylthiopropylamineIBA 01/2017

Therapy/Procedure

54	Castration 03/2024 - 04/2009
28	Therapeutics 03/2024 - 01/2009
10	Drug Therapy (Chemotherapy) 07/2023 - 03/2006
3	Aftercare (After-Treatment) 01/2023 - 08/2015
3	Radiotherapy 09/2021 - 08/2015
2	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 08/2015
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Infant Equipment (Crib) 01/2021